Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Trioxsalen (25mg) Tablet
Therapeutic Category
Dermatology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹171/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Trifoli 25 Tablet contains Trioxsalen, a psoralen derivative used in combination with ultraviolet A (UVA) light therapy to treat certain skin conditions. It works as a photosensitizing agent that, upon activation by UVA light, interacts with DNA in skin cells to regulate abnormal cell growth and pigmentation. The 25 mg strength is typically used as part of PUVA (Psoralen + UVA) therapy. Trioxsalen helps repigment skin in conditions such as vitiligo and reduces excessive cell proliferation in psoriasis. It is also used in some cases of eczema and cutaneous T-cell lymphoma under specialist supervision. Trifoli 25 enhances melanin production in the skin, aiding in the restoration of normal pigmentation when used appropriately with controlled UVA exposure.
Common side effects include nausea, itching, mild redness, or dryness of the skin after UVA exposure. Some patients may experience headache or dizziness. Serious but rare adverse effects include blistering, severe phototoxic reactions, hyperpigmentation, premature skin aging, or an increased long-term risk of skin cancer if PUVA therapy is not carefully monitored. Eye sensitivity to light may also occur, requiring protective eyewear.
Trifoli 25 Tablet is indicated for the treatment of vitiligo, particularly for inducing repigmentation in depigmented patches, and for the management of psoriasis and other PUVA-responsive dermatoses. It may also be prescribed for certain cases of mycosis fungoides (cutaneous T-cell lymphoma).
Trifoli 25 Tablet should only be taken under dermatological supervision as part of a controlled PUVA therapy protocol. Patients must strictly follow the recommended UVA exposure schedule to avoid burns or phototoxic damage. Protective eyewear must be worn during and after treatment to prevent eye damage and cataract formation. It is contraindicated in pregnancy, breastfeeding, and in patients with a history of skin cancer, lupus, or photosensitivity disorders. Avoid sun exposure for at least 8 hours after taking the tablet unless under medical guidance, as it can cause severe burns. Regular monitoring by a healthcare professional is essential to ensure safe and effective therapy.
Store Trifoli 25 Tablet in a cool, dry place below 25–30°C, protected from light and moisture. Keep the medication in its original packaging and out of reach of children. Do not use after the expiry date printed on the strip.
Composition : Methoxsalen 20mg Tablets
Composition : Clindamycin (300mg)
Composition : Itraconazole (100mg)
Composition : Itraconazole (200mg)
Composition : Itraconazole (130mg) Capsule
Composition : Neem & Aloe Vera Face Wash
Composition : Salycylic Acid 2% w/v Foaming Facewash
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Trioxsalen 25mg Tablet has niche demand in the dermatology, phototherapy, and specialty healthcare segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on dermatology and specialty care portfolios.
Medical distributors and agencies can benefit from demand in specialized dermatology practices for photochemotherapy (PUVA) under strict medical supervision. Trioxsalen 25mg is a psoralen (photosensitizing agent) that increases the skin's sensitivity to ultraviolet A (UVA) light during PUVA (Psoralen + UVA) therapy Commonly prescribed in combination with controlled UVA exposure for the treatment of selected patients with vitiligo, psoriasis, and certain other dermatological conditions, as advised by dermatologists and according to approved indications Helps promote repigmentation in vitiligo and reduces excessive skin cell proliferation in psoriasis when used as part of a supervised PUVA treatment protocol Oral tablet formulation is administered before scheduled UVA phototherapy sessions, with dosage and timing individualized by the treating dermatologist Treatment should be carried out only under specialist supervision. Patients require appropriate eye protection, sun protection, and monitoring due to the risk of phototoxic reactions, skin burns, premature skin aging, and increased long-term risk of skin malignancy associated with PUVA therapy Frequently utilized in dermatology clinics, phototherapy centers, specialty hospitals, and tertiary care institutions Widely prescribed by dermatologists experienced in PUVA therapy for appropriately selected patients This strengthens a comprehensive dermatology and specialty phototherapy portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Trioxsalen 25mg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from specialty dermatology market demand, institutional procurement opportunities, reliable supply chain support, niche product positioning, and attractive margins in the dermatology segment.
Interested distributors, stockists, wholesalers, and institutional suppliers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality dermatology and specialty healthcare products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.